



State of Fertility in X and Y Chromosomes Variations Individuals *What You Should Know in 2025*

Hooman Sadri MD, PhD

Associate Professor of Urology, Pediatrics, Pathology & Regenerative Medicine
Director of Male Fertility Research Program

26 July 2025 Atlanta



Disclosures

- Active Patent: **5/294,154 | 9865-185**
- **METHOD OF PRODUCING IN VITRO**
- **TESTICULAR CONSTRUCTS AND USES THEREOF**

Application AU2019200730A events

Priority claimed from

US201161492151P

2019-02-04

[Application filed by Inguran LLC](#)

2019-02-04

[Priority to AU2019200730A](#)

2019-02-21

[Publication of AU2019200730A1](#)

2021-08-12

Application granted

2021-08-12

[Publication of AU2019200730B2](#)

Status


Active

2032-06-01

Anticipated expiration

Objectives

- Infertility in general population (Male & Female)
- Fertility in Klinefelter syndrome
- Fertility in Triple X syndrome
- Current clinical options to treat infertility
- Future options to treat infertility



Terminology

Fertility refers to the capability to **conceive or induce a pregnancy**.

Fecundity refers to the probability of producing a **live birth** arising from a given menstrual cycle.

Infertility is the term used when a couple **fails** to induce a pregnancy within **one year** of regular unprotected intercourse.

Primary infertility defines the condition when **no pregnancy at all** has been Achieved.

Secondary infertility means **no further** pregnancies have occurred. The term infertile can be applied to both men and women.




Infertility Prevalence



One out of every six couples experiences infertility.



The Infertility Problem




Affects 6-8 million couples in US (NSFG 2002, NICHD)

Interdependence of male and female reproductive functions

Male reproductive functions		Female reproductive functions		
		absent	impaired	optimal
		absent	impaired	optimal
		absent	impaired	optimal
optimal	3	2	1	
impaired	5	4	2	
absent	5	5	3	

Classification of causes of the male infertility



PRE-TESTICULAR

- Congenital
 - Kallman syndrome
 - Laurence-Moon-Bardet-Biedl syndrome
 - Prader-Willi syndrome
- Acquired
 - Hypopituitarism
 - Tumor
 - Ischemia
 - Post-surgical
 - Radiation
 - Endocrinopathy
 - Hyperprolactinemia
 - Exogenous testosterone
 - Excess estrogen

Idiopathic

TESTICULAR

- Congenital
 - Chromosomal abnormalities
 - Klinefelter syndrome
 - Y-chromosome microdeletions
 - Noonan syndrome
 - Cryptorchidism
- Acquired
 - Varicocele
 - Torsion
 - Orchitis
 - Gonadotoxins: radiation, chemotherapy and heat
- Idiopathic

POST-TESTICULAR


- Congenital
 - CBAVD/cystic fibrosis
 - Utricular/müllerian duct cysts
 - Atresia/stenosis of the ejaculatory ducts
- Acquired
 - Anatomic obstruction
 - Ejaculatory ducts
 - Vas deferens
 - Retrograde ejaculation
 - Penile deformities
 - Erectile dysfunction
 - Failure of emission/ejaculation
- Idiopathic

Distribution of Diagnostic Categories

Category	N	%
Varicocele	629	26.4
Infectious	72	3.0
Hormonal	54	2.3
Ejaculatory dysfunction	28	1.2
Systemic diseases	11	0.4
Idiopathic	289	12.1
Immunologic	54	2.3
Obstruction	359	15.1
Cancer	11	0.5
Cryptorchidism	342	14.3
Genetic	189	7.9
Testicular failure	345	14.5
TOTAL	2,383	100.0


Semen Analysis

- 2-3 days of abstinence
- Collection technique
- Note: SA best performed in andrology lab;
If abnormal **always repeat**



Semen parameter	WHO 1980	WHO 1987	WHO 1992	WHO 1999	WHO 2010 ¹	WHO 2021
Volume (mL)	ND	≥2	≥2	≥2	1.5	1.4
Sperm concentration (x10 ⁶ /mL)	20-200	≥20	≥20	≥20	15	16
Total sperm number (x10 ⁶)	ND	≥40	≥40	≥40	39	39
Total motility (%)	≥60	≥50	≥50	≥50	40	42
Progressive motility (%) ²	≥2 ³	≥25	≥25 (grade a)	≥25 (grade a)	32 (a+b)	30
Vitality (%)	ND	≥50	≥75	≥75	58	54
Normal morphology (%)	80.5	≥50	≥30	(14)	4	4


Sperm count vary over time



THE FEMALE FERTILITY CYCLE

How it works

- 1 **Pituitary gland**
Pituitary hormones cause ovary to start maturing an egg
- 2 Hormone **estrogen** signals follicle to rupture and release mature egg (ovulation)
- 3 Outspread **fimbria** direct egg into the fallopian tube
- 4 Egg fertilized by sperm becomes a **zygote**
- 5 **Zygote**, with chromosomes from mother and father, divides and becomes an **embryo**
- 6 Cells divide as embryo travels down fallopian tube
- 7 Embryo implants in uterine wall



Where problems can develop

FALLOPIAN-TUBE BLOCKAGE

30% of infertility cases. Tumor, scar tissue or spreading tissue (endometriosis) blocks tube.

Surgery can fix some blockage. Implanting embryo into uterus can bypass the fallopian tube.

HORMONE IMBALANCE

15% to 30% of female infertility. Eggs aren't formed and released properly. Hormone therapy may help.

UTERINE LINING

Inadequate progesterone hormone makes uterine lining unable to maintain pregnancy

CERVIX

Mucus fails to thin before ovulation; sperm can't survive. Estrogen therapy may help, or sperm may be deposited directly into uterus.

MCT

SOURCES: "ABCs of the Human Body," "Mayo Clinic Family Health Book,"

Common Causes Female Infertility

Ovulation Disorders Causes:

- Aging
- Diminished ovarian reserve
- Premature ovarian failure
- Endocrine disorders (as PCOS)

Tubal Causes:

- Pelvic inflammatory disease
- Tubal Surgery
- Previous ectopic pregnancy
- Salpingectomy

Uterine/Cervical Causes:

- Congenital uterine anomaly
- Fibroids
- Endometriosis
- Poor cervical mucus quantity/quality
- Infection





TABLE 4.14 Incidences of Selected Chromosomal Abnormalities in Live-Born Infants

Abnormality	Incidence in Live Births
Autosomal trisomies	
Trisomy 21 (Down syndrome)	1:650 to 1:1,000
Trisomy 13 (Patau syndrome)	1:4,000 to 1:10,000
Trisomy 18 (Edwards syndrome)	1:3,500 to 1:7,500
Sex chromosome disorders	
45,X (Turner syndrome)	1:2,500 to 1:8,000 females
47,XXX (triple X)	1:850 to 1:1,250 females
47,XXY (Klinefelter syndrome)	1:500 to 1:1,000 males
47,XYY (Jacobs syndrome)	1:840 to 1:1,000 males
Structural abnormalities	
Rearrangements (e.g., translocations, deletions)	~1:440 live births

Note: Based on statistics from surveys in different populations and not age adjusted. Data prior to use of prenatal diagnosis and selective termination of pregnancies became widespread.



Normal Karyotype

Male

Klinefelter Syndrome (KS)

- First described in 1942 as an “endocrine disorder”
- Extra-X chromosome identified in 1959; re-classified as “chromosomal disorder”




Harry F. Klinefelter, MD

KS Prevalence

- 1 in 500 men
- Most common sex chromosome disorder in men
- Most common genetics cause of male infertility

Error in Cell Division

- Usually, a random error
- Either the egg or the sperm can have an imbalance in number of chromosomes



KS Variability!




- 47,XXY } 80-90% of KS patients
 - Extra X chromosomes
(48,XXXY, 49XXXXY etc.)
 - Mosaicism (46,XY/47,XXY)
 - Structurally abnormal X chromosome
- 10-20% of KS patients
- The “classic” KS patient is....not so classic

Testosterone (T) Production

- T levels are normal in infants and pre-pubertal boys
- Most boys initiate puberty normally, but might fail to progress
- T levels rise in early puberty, plateau in the low-normal range in mid-puberty, then decline


Hormone Levels

Pituitary Gland



Eberhard Nieschlag 2013

Sperm Production



- Klinefelter syndrome
 - Germ cells do not progress normally to produce sperm
 - Seminiferous tubes become scarred
 - Rare areas of sperm production are possible

Testicular Size

- Boys with KS have smaller testes compared to their peers
- Testicular growth briefly increases after the onset of puberty to mid-puberty, then declines



Puberty: A Critical Time

- Decline in testicular function begins shortly after entering puberty
- This is the time to consider testosterone therapy
- This is also the time to think about fertility preservation

Testosterone Therapy (TRT)

- Testosterone supplementation is helpful because testosterone plays many important roles:
 - Promotes growth
 - Increases muscle mass
 - Preserves bone density
 - Allows development of secondary sexual characteristics
 - Has positive psychological benefits
 - May increase libido and improve erection function


Testosterone therapy does **not** improve spermatogenesis and should **not** be used by men of reproductive age



Male Contraception

Options

- Use non-testosterone based hormone therapies
 - hCG
 - Clomiphene citrate
 - Anastrozole/Letrozole
- Nasal Testosterone



Nasal Gel Testosterone

One pump (5.5 mg) in each nostril 3 times daily, for a total daily dose of 33 mg

Each dose should be taken 6 to 8 hours apart: once in the morning, once in the afternoon, once in the evening



Natesto appears to increase testosterone while maintaining semen parameters in a majority of men.

[Clinical Trial](#) > [J Urol.](#) 2020 Sep;204(3):557-563. doi: 10.1097/JU.0000000000001078.

Epub 2020 Apr 15.

Effect of Natesto on Reproductive Hormones, Semen Parameters and Hypogonadal Symptoms: A Single Center, Open Label, Single Arm Trial

Ranjith Ramasamy¹, Thomas A Masterson¹, Jordan C Best¹, Joshua Bitran¹, Emad Ibrahim¹, Manuel Molina¹, Ursula B Kaiser², Feng Miao³, Isildinha M Reis^{3,4}

Affiliations + expand

PMID: [32294396](#) DOI: [10.1097/JU.0000000000001078](#)


Received: 16 March 2022 | Revised: 7 April 2022 | Accepted: 18 April 2022
DOI: [10.1111/and.14453](#)

ORIGINAL ARTICLE

ANDROLOGIA WILEY

Direct conversion from long-acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept

Parviz K. Kavoussi[✉] | Graham L. Machen[✉] | Shu-Hung Chen | Melissa S. Gilkey | Justin Chen | Yazan Hamzeh | Kenneth I. Aston | Shahryar K. Kavoussi



Sunday, July 27

7:30-9am – Breakfast Buffet


8:30-3pm – Childcare



Room	9-10am Session 7	10-11am Session 8	11am-12pm Session 9	12-1:30pm Lunch and Poster Session	1:45-3pm Session 10
Emory Amphitheater (Live Streamed & Recorded) **	Unpacking Social and Emotional Challenges for Teens/Young Adults with X/Y Variations Caitlin Middleton Kate Deer Rebecca Wilson	Eval and Treatment Of ADHD & Anxiety In Children Caitlin Middleton Ciara Gurley	Understanding X and Y Variations: Genetic Diagnosis, Terminology & Next Steps Planning Susan Howell Kayla Molison		Support Groups by Genetic Signature
Oak Amphitheater	Supporting Academic and Social-Emotional Education of Students with X&Y Chromosome Variations Amy Talboy Catherine Trapani	Testosterone Treatment Options in Klinefelter Syndrome Hooman Sadri	What Adults with X/Y Variations Want Parents and Others to Know Panel Discussion Mod. by Sharron Close		Support Groups by Genetic Signature
Azalea	Tips for Staying Healthy for Teens and Adults with X and Y Chromosome Variations Maria Vogiatzi	X/Y Chromosome Variations and Autism: Insights from Large Scale Population Research Matthew Oetjens	Promoting physical activity in Children with XXY T. Zachary Huit		Support Groups by Genetic Signature
Mt. Laurel	Disclosing the Diagnosis- Panel Discussion Mod. by Susan Howell	Unassigned	Unassigned		Support Groups by Genetic Signature
Hickory	Unassigned	Unassigned	Unassigned		Support Groups by Genetic Signature
Dorwood	Unassigned	Unassigned	Unassigned		Support Groups by





Fertility Preservation Consultation & Services




Physical Exam (sexual maturity)

Tanner Staging





Special Elastography Ultrasound (stiffness; Fibrosis)






One Step Encounter Fertility Preservation

FIGURE 1



Sadri-Ardekani et al, *Fertility and Sterility* 2013


Microscopic Testicular Sperm Extraction (mTESE)




Clinical Andrology 2011, EAU/ESAU Course Guidelines; Edited by L Björndahl, A Giwercman, H Tournaye and W Weidner

Medical and Surgical Management of Male Infertility 2014; Edited by Rizk, Aziz & Agarwal

In Vitro Fertilization (IVF) using stored sperms



Intra-cytoplasmic sperm injection (ICSI)



April 1991- Jan 1992

Overall Sperm Retrieval : 44%
Overall Live Birth Rate per ICSI cycle: 43%

Clinical Andrology 2011, EAU/ESAU Course Guidelines; Edited by L Björndahl, A Giwercman, H Tournaye and W Weidner

Medical and Surgical Management of Male Infertility 2014; Edited by Rizk, Aziz & Agarwal

Corona et al 2017, HRU

Pre-Implantation Genetic Diagnosis (PGD)



(Fresh) mTESE
(at least 70% chance
of finding sperm)




ICSI/PGTA



Pregnancy (70% per Embryo Transfer if partner is <35 yr old)



From Spermatogonia Stem Cell to Sperm



© 2013 Encyclopædia Britannica, Inc.


Age-related presence of spermatogonia in patients with Klinefelter syndrome: a systematic review and meta-analysis

Nicholas A. Deebel^{1,2}, Guillermo Galdon², Nima Pourhabibi Zarandi², Kimberly Stogner-Underwood³, Stuart Howards¹, James Lovato⁴, Stanley Kogan^{1,2}, Anthony Atala^{1,2}, Yanhe Lue⁵, and Hooman Sadri-Ardekani^{1,2,*}

¹Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, USA ²Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA ³Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA ⁴Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA ⁵Division of Endocrinology, Department of Medicine, Los Angeles Biomedical Research Institute and Harbor-UCLA Medical Center, Torrance, CA, USA

*Correspondence address: 391 Technology Way (WFIRM), Winston-Salem, NC 27101, USA. Tel: +1 336-713-1493; Fax: +1 336-713-5754; E-mail: hsadri@wakehealth.edu orcid.org/0000-0003-4377-4404

Submitted on June 4, 2019; resubmitted on September 15, 2019; editorial decision on September 30, 2019







Morphometric and immunohistochemical analysis as a method to identify undifferentiated spermatogonial cells in adult subjects with Klinefelter syndrome: cohort study

Nicholas A. Deebel, M.D.,^{a,b} Haleh Soltanghorae, M.D.,^{c,d} Aaron William Bradshaw, M.D.,^{a,b} Omar Abdelaal, M.D.,^{b,e} Karl Reynolds, B.S.,^b Stuart Howards, M.D.,^a Stanley Kogan, M.D.,^{a,b} Mohammad Reza Sadeghi, Ph.D.,^{c,d} Anthony Atala, M.D.,^{a,b} Kimberly Stogner-Underwood, M.D.,^{a,e} and Hooman Sadri-Ardekani, M.D., Ph.D.^{a,b,f}

^a Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; ^b Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina; ^c Reproductive Biotechnology Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research, Tehran, Iran; ^d Avicenna Infertility Clinic, Avicenna Research Institute, Academic Center for Education, Culture and Research, Tehran, Iran; ^e Department of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; and ^f Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

Fertil Steril. 2022 Nov;118(5):864-873





Testicular Tissue Banking

for Fertility Preservation in
Boys and Men at Risk for Infertility



Cancer	Bilateral UDT	Klinefelter	Registry	denied

IRB approval
March 2013

Good Tissue Practice (GTP)
regulations

FDA registration
June/July 2014

First patient recruitment
07/22/2014

221 Patients

12

Updated July 25, 2025



Atrium Health

* One subject was Klinefelter and suffered from the cancer too.



Wake Forest®
School of Medicine

Check for updates

OPEN ACCESS

EDITED BY
Rick Francis Thorne,
The University of Newcastle, Australia

REVIEWED BY
Yi Zheng,
Northwest A&F University, China
Peter Schlegel,
NewYork-Presbyterian, United States

*CORRESPONDENCE
Hooman Sadri-Ardekani
hsadri@wakehealth

SPECIALTY SECTION
This article was submitted to
Reproduction, a section of the journal
Frontiers in Endocrinology


RECEIVED 25 July 2022
ACCEPTED 05 September 2022
PUBLISHED 28 September 2022

CITATION

Galdon G, Deebel N, Wang C, Lue S, Pettenati M, Stogner K, Kogan J, Howards S, Sadri-Ardekani H

In vitro propagation of XXY human Klinefelter spermatogonial stem cells: A step towards new fertility opportunities

Guillermo Galdon^{1,2}, Nicholas A. Deebel^{1,3}



type,
and




FIGURE 6
(A) Spermatogonial stem cells (SSC) population was estimated by combining HLA-/CD9+/CD49f+ markers on Flow Cytometry analysis. After 68 days in culture and nine passages, the percentage of putative SSC was 10.1% of a 17-year-old KS patient (B). Several time points were analyzed to evaluate the evolution of this population over time in all subject samples in culture. The graph shows the average of the SSCs population during the culture in KS patients (B).

Article

In Vitro Generation of Haploid Germ Cells from Human XY and XXY Immature Testes in a 3D Organoid System

Guillermo Galdon^{1,2,*}, Nima Pourhabibi Zarandi^{1,3}, Nicholas A. Deebel^{1,4}, Sue Zhang^{1,5}, Olivia Cornett¹, Dmitry Lyalin^{6,7}, Mark J. Pettenati⁶, YanHe Lue⁸, Christina Wang⁸, Ronald Swerdloff⁸, Thomas D. Shupe¹, Colin Bishop¹, Kimberly Stogner^{1,6}, Stanley J. Kogan¹, Stuart Howards^{1,4}, Anthony Atala^{1,4} and Hooman Sadri-Ardekani^{1,4,6,*}


¹ Wake Forest Institute for Regenerative Medicine (WIRM), Wake Forest School of Medicine, Winston-Salem, NC 27101, USA

² Facultad de Medicina, Universidad de Barcelona, 08036 Barcelona, Spain

³ Department of Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, PA 17101, USA

⁴ Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

Spermatogenesis



Citati
Deebel
Lyalin
Wang,
Cener
from I
Testes
Bioeng
https:
bioengi
Acade
A. Ver



Received: 22 June 2022
Revised: 22 June 2022
Accepted: 22 June 2022
Published: 3 July 2022

noide;

Creating the 3D Organoids (HTO); Methods




Ultra Low Attachment Round-bottom plates




Pendergraft et al 2017
Galdon et al 2024


In Vitro Formed HUMAN Haploid Germ cells; DNA FISH



Human Testicular
Organoid (HTO)



X, Y, 18



Galdon et al 2024



The U.S. government does not review or approve the safety and science of all studies listed on this website.

Read our full [disclaimer](#) for details.



Recruiting ⓘ

Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples (ROSI)

ClinicalTrials.gov ID ⓘ NCT04298255

Sponsor ⓘ Wake Forest University Health Sciences

Information provided by ⓘ Wake Forest University Health Sciences (Responsible Party)

Last Update Posted ⓘ 2025-05-30

Download

Save

+ Expand all content

— Collapse all content

Feedback

Ninety babies born after round spermatid injection into oocytes: survey of their development from fertilization to 2 years of age

Atsushi Tanaka, M.D., Ph.D.,^a Kohta Suzuki, M.D., Ph.D., M.P.H.,^b Motoki Nagayoshi, M.D.,^a Akihiro Tanaka, M.B.I.T.,^a Youichi Takemoto,^a Seiji Watanabe, Ph.D.,^c Satoru Takeda, M.D., Ph.D.,^d Minoru Inahara, M.D., Ph.D.,^e Naoki Kuji, M.D., Ph.D.,^f Zentaro Yamagata, M.D., Ph.D.,^g and Ryuzo Yanagimachi, Ph.D.^h


^a Saint Mother Obstetrics and Gynecology Clinic and Institute for Assisted Reproductive Technologies, Fukuoka, Japan; ^b Department of Health and Psychosocial Medicine, Aichi Medical University School of Medicine, Aichi, Japan; ^c Department of Anatomic Science, Hiroaki University Graduate School of Medicine, Hiroaki, Japan; ^d Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo, Japan; ^e Department of Obstetrics and Gynecology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan; ^f Department of Obstetrics and Gynecology, Tokyo Medical College, Tokyo, Japan; ^g Basic Science for Clinical Medicine, Division of Medicine, Graduate School Department of Interdisciplinary Research, University of Yamanashi, Yamanashi, Japan; and ^h University of Hawaii Medical School, Honolulu, Hawaii

Objective: To compare physical and cognitive development of babies born after round spermatid injection (ROSI) with those born after natural conception.
Design: Comparison of efficiencies of ROSI and ICSI using testicular spermatozoa, performed in the St. Mother Clinic. Physical and cognitive development of ROSI babies recorded by parents in the government-issued Mother-Child Handbook was checked and verified by attending pediatricians. Data included baby's weight gain and response to parents' voice/gesture.
Setting: Assisted reproduction technology practice.
Patient(s): A total of 721 men participated in ROSI; 90 ROSI babies were followed for 2 years for their physical and cognitive development. Control subjects were 1,818 naturally born babies.
Intervention(s): Surgical retrieval of spermatogenic cells from testes; selection and injection of round spermatids into oocytes; oocyte activation, in vitro culture of fertilized eggs, and embryo transfer to mothers.
Main Outcome Measure(s): Physical and cognitive development of ROSI babies (e.g., body weight increase, response to parents, and understanding and speaking simple language) compared with naturally born babies.
Result(s): Of 90 ROSI babies, three had congenital aberrations at birth, which corrected spontaneously (ventricular septal or after surgery [cleft lip and embolus]). Physical and cognitive development of ROSI babies was similar to those of naturally born babies.
Conclusion(s): There were no significant differences between ROSI and naturally conceived babies in either physical or cognitive development during the first 2 years after birth.
Clinical Trial Registration Number: UMIN Clinical Trials Registry UMIN000006117. [Fertil Steril® 2018;110(4):51. Copyright © 2018 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)]
El resumen está disponible en Español al final del artículo.


Key Words: Assisted fertilization, human egg, physical and cognitive development, round spermatid injection
Discuss: You can discuss this article with its authors and other readers at <https://www.fertsteridialog.com/users/16110-fertility-and-sterility/posts/32485-25452>

Received December 13, 2017; revised April 9, 2018; accepted April 24, 2018.
Atsushi T. has nothing to disclose. K.S. has nothing to disclose. M.M. has nothing to disclose. Akihiro T. has nothing to disclose. Y.T. has nothing to disclose. S.W. has nothing to disclose. S.T. has nothing to disclose. M.I. has nothing to disclose. N.K. has nothing to disclose. Z.Y. has nothing to disclose. R.Y. has nothing to disclose.
A.T. and K.S. should be considered similar in author order.
Reprint requests: Atsushi Tanaka, M.D., Ph.D., Saint Mother Obstetrics and Gynecology Clinic, 4-8-12 Ori-to Yahatanishi-ku Kitakyushu, Fukuoka, Japan (E-mail: info@stmother.com).

Fertility and Sterility® Vol. 110, No. 3, August 2018 0015-0282
Copyright © 2018 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<https://doi.org/10.1016/j.fertster.2018.04.033>



Normal Karyotype
Female



History


- The first published report of a woman with a 47,XXX karyotype was by Patricia A. Jacobs, in Edinburgh, Scotland in 1959. She was a 35-year-old, 5 ft. 9 in., 128 lb. woman who had premature ovarian failure at age 19; her mother was age 41 and her father was 40 at the time of her conception.
- Occurs more often when older men and women conceive vs. younger couples.

Triple X Syndrome

- One in every 1000 females has an extra X chromosome
- The most common sex chromosome abnormality in females
- Most individuals with 47,XXX are diagnosed **incidentally** on prenatal genetic screening
- The physical phenotype shows earlier growth and longer legs. 47,XXX females have a tendency to be tall, with many reaching the 80th percentile in height by adolescence, but with an average head circumference between the 25th to 35th percentile
- **Puberty and fertility** are generally in the **normal** range, but **premature ovarian failure** can occur

One of the hidden causes of early menopause
is **premature ovarian failure (POF)**, which

refers to ovaries
problems before
the age of 40.



Premature ovarian failure (POF) is a condition in which the ovarian functions of **hormone production** and **oocyte (egg) development** become impaired before the typical age for menopause.

POF occurs in approximately 1% of all women

Studies on the prevalence of POF in adolescents or adults with trisomy X have not yet been performed


Premature ovarian failure (POF) seems to be **somewhat** more common than in the general population

Summary

- Infertility is common in general population (15%)
- More than 98% of **Klinefelter** individuals deal with infertility
- Early Fertility Preservation is recommended before long term Testosterone replacement
- Microsurgical Testicular Sperm Extraction (**Micro-TESE**) and Intra Cytoplasmic Sperm Injection (**ICSI**) is the most successful clinical option in Klinefelter syndrome
- **Spermatogonial Stem Cell** Technology is a great hope for the future
- Infertility is not an issue in most of the **Triple X** individuals; however they need a good reproductive health management
- Egg Freezing (Triple X)

- Appointment for initial evaluation and consultation (In Person Only):

336.713.1493



- Appointment for initial evaluation and consultation (Virtual for Non-NC Residents or In-Person):

336.448.9100



Charlotte, North Carolina
Greensboro, North Carolina
Winston-Salem, North Carolina



Hooman Sadri, MD PhD

Cell Phone (Text Only):
336.745.7034

E-Mail: hsadri@cfi.clinic



Winston-Salem, North Carolina
Greensboro, North Carolina



Charlotte, North Carolina
Mooresville, North Carolina
Greensboro, North Carolina
Winston-Salem, North Carolina



